Key result
Review outlines evidence and guidance for lipid- and glucose-lowering therapies in MASLD-associated dyslipidemia.
Answers are grounded in this paper and cite their sources.
This review highlights the need for a holistic approach to managing dyslipidemia, glucose levels, and body weight in patients with MASLD using various lipid- and glucose-lowering therapies.
Dyslipidemia is a major risk factor for cardiovascular disease, and its impact may be exacerbated when accompanied by metabolic dysfunction-associated steatotic liver disease (MASLD). The simultaneous management of these conditions poses multiple challenges for healthcare providers. Insulin resistance has been implicated in the pathogenesis of both dyslipidemia and MASLD, necessitating a holistic approach to managing dyslipidemia, glucose levels, body weight, and MASLD. This review explores the intricate pathophysiological relationship between MASLD and dyslipidemia. It also examines current guidance regarding the use of lipid-lowering agents (including statins, ezetimibe, fibrates, omega-3 polyunsaturated fatty acids, and proprotein convertase subtilisin/kexin type 9 inhibitors) as well as glucose-lowering medications (such as pioglitazone, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors) in patients with MASLD, with or without metabolic dysfunction-associated steatohepatitis (MASH), and dyslipidemia. Additionally, the review addresses the potential of emerging drugs to concurrently target both MASLD/MASH and dyslipidemia. Our hope is that a deeper understanding of the mechanisms underlying MASLD and dyslipidemia may assist clinicians in the management of these complex cases.
No takes yet. Share an insight, caveat, or question.
Bril et al. (2025) conducted a review in Dyslipidemia and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Lipid-lowering and glucose-lowering medications was evaluated. This review explores the pathophysiological relationship between MASLD and dyslipidemia and examines current guidance for using lipid-lowering and glucose-lowering medications in these patients.
Synapse has enriched 10 related papers. Consider them for comparative context: